Outcome of optic disc capillary hemangioma following intravitreal ranibizumab injection: A case report.

IF 1.4 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL
Journal of International Medical Research Pub Date : 2025-04-01 Epub Date: 2025-04-11 DOI:10.1177/03000605251328621
Miao Hao, Fengjiao Li, Suzhen Zhao, Yalin Wang, Shengnan Ma, Weiyan Zhou
{"title":"Outcome of optic disc capillary hemangioma following intravitreal ranibizumab injection: A case report.","authors":"Miao Hao, Fengjiao Li, Suzhen Zhao, Yalin Wang, Shengnan Ma, Weiyan Zhou","doi":"10.1177/03000605251328621","DOIUrl":null,"url":null,"abstract":"<p><p>Optic disc capillary hemangiomas, a rare capillary hamartoma that often invades optic nerve fibers and disc plaque bundles, have been a therapeutic challenge for ophthalmologists in recent years due to their unique location. A woman in her early 50s presented with blurred vision in the right eye for 2 days. On ocular examination, her best-corrected visual acuity was 20/340 in the right eye. Wide-field fundus imaging revealed a red mass on the temporal side of the optic disc. Optical coherence tomography revealed macular edema. The diagnosis was optic disc capillary hemangioma. Subsequently, 0.5 mg ranibizumab was intravitreally injected into the right eye once monthly, for a total of two injections. The patient was re-examined at 15 days, 50 days, and 21 months after the first operation. The patient's postoperative best-corrected visual acuity improved to 20/60, and macular edema and exudation were reduced in the short term compared with those in the previous period; however, the tumor did not change significantly. The anti-vascular endothelial growth factor agent ranibizumab is effective in treating optic disc capillary hemangiomas.</p>","PeriodicalId":16129,"journal":{"name":"Journal of International Medical Research","volume":"53 4","pages":"3000605251328621"},"PeriodicalIF":1.4000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12033708/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of International Medical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03000605251328621","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/11 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Optic disc capillary hemangiomas, a rare capillary hamartoma that often invades optic nerve fibers and disc plaque bundles, have been a therapeutic challenge for ophthalmologists in recent years due to their unique location. A woman in her early 50s presented with blurred vision in the right eye for 2 days. On ocular examination, her best-corrected visual acuity was 20/340 in the right eye. Wide-field fundus imaging revealed a red mass on the temporal side of the optic disc. Optical coherence tomography revealed macular edema. The diagnosis was optic disc capillary hemangioma. Subsequently, 0.5 mg ranibizumab was intravitreally injected into the right eye once monthly, for a total of two injections. The patient was re-examined at 15 days, 50 days, and 21 months after the first operation. The patient's postoperative best-corrected visual acuity improved to 20/60, and macular edema and exudation were reduced in the short term compared with those in the previous period; however, the tumor did not change significantly. The anti-vascular endothelial growth factor agent ranibizumab is effective in treating optic disc capillary hemangiomas.

玻璃体内注射雷尼单抗治疗视盘毛细血管瘤1例。
视盘毛细血管瘤是一种罕见的毛细血管错构瘤,常侵犯视神经纤维和椎间盘斑块束,由于其独特的位置,近年来一直是眼科医生的治疗挑战。一位50岁出头的女性,右眼视力模糊2天。眼科检查,右眼最佳矫正视力为20/340。眼底宽视场成像显示视盘颞侧有一红色肿块。光学相干断层扫描显示黄斑水肿。诊断为视盘毛细血管瘤。随后,0.5 mg雷尼单抗被每月一次通过玻璃体注射到右眼,共注射两次。患者于第一次手术后15天、50天和21个月复查。患者术后最佳矫正视力改善至20/60,短期内黄斑水肿、渗出较前期减少;然而,肿瘤没有明显变化。抗血管内皮生长因子药物雷尼珠单抗治疗视盘毛细血管瘤有效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.20
自引率
0.00%
发文量
555
审稿时长
1 months
期刊介绍: _Journal of International Medical Research_ is a leading international journal for rapid publication of original medical, pre-clinical and clinical research, reviews, preliminary and pilot studies on a page charge basis. As a service to authors, every article accepted by peer review will be given a full technical edit to make papers as accessible and readable to the international medical community as rapidly as possible. Once the technical edit queries have been answered to the satisfaction of the journal, the paper will be published and made available freely to everyone under a creative commons licence. Symposium proceedings, summaries of presentations or collections of medical, pre-clinical or clinical data on a specific topic are welcome for publication as supplements. Print ISSN: 0300-0605
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信